Suramin in non-small cell lung cancer and advanced breast cancer. Two parallel phase II studies

Acta Oncologica

Volumn 36, Issue 2, 1997, Pages 171-174

  Mirza, Mansoor R ^a   Jakobsen, Erik ^a   Pfeiffer, Per ^a   Lindebjerg Clasen, Bente ^a   Bergh, Jonas ^b   Rose, Carsten ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UPPSALA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

SURAMIN;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; FEMALE; HUMAN; LUNG NON SMALL CELL CANCER; MALE; NEUROTOXICITY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; TREATMENT FAILURE;

EID: 0030891264     PISSN: 0284186X     EISSN: None     Source Type: Journal    
DOI: 10.3109/02841869709109226     Document Type: Article

References (23)

1. Suramin. In: Reynolds JEF, ed. Martindale, the extra pharmacopoeia. London: The Pharmaceutical Press, 1989; 679-80.
2. Hawking F. Suramin: With special reference to onchocerciasis. Adv Pharmacol Chemother 1978; 15: 289-322.
3. De Clercq E. Suramin: a potent inhibitor of the reverse transcriptase of RNA tumor viruses. Cancer Letts 1979; 8: 9-22.
4. Wade T, Kasid A, Stein C, et al. Suramin interference with transforming growth factor-β inhibition of human renal cell carcinoma in culture. J Surg Res 1992; 53: 195-8.
5. Cardinali M, Sartor O, Robbins K. Suramin, an experimental chemotherapeutic drug, activates the receptor for epidermal growth factor and promotes growth of certain malignant cells. J Clin Invest 1992; 89: 1242-7.
6. Hensey C, Boscoboinik D, Assi A. Suramin, anti-cancer drug, inhibits protein kinase C and induces differentiation in neuroblastoma cell clone NB2A. FEBS Lett 1989; 258: 156-8.
7. Grazioli L, Alzani R, Ciomei M, et al. Inhibitory effect of Suramin on receptor binding and cytotoxic activity of tumor necrosis factor. Int J Immunopharmac 1992; 14: 637-42.
8. Mills G, Zhang N, May C, Hill M, Chung A. Suramin prevents binding of interleukin 2 to its cell surface receptor: A possible mechanism for immunosuppression. Cancer Res 1990; 50: 3036-42.
9. Rossi M, Zetter B. Selective inhibition of prostatic carcinoma cell by transferrin. Proc Natl Acad Sci USA 1992; 89: 6197-201.
10. Schneider W, Beisiegel U, Goldstein J, Brown M. Purification of the low density lipoprotein receptor, an acidic glycoprotein of 164000 molecular weight. J Biol Chem 1982; 257: 2664-73.
11. Braddock P, Hu D-E, Fan T-P, Stratford I, Harris A, Bicknell R. A structure-activity analysis of antagonism of the growth factor and angiogenic activity of fibroblast growth factor by suramin and related polyanions. Br J Cancer 1994; 69: 890-8.
12. Pesenti E, Sola F, Mongelli N, Grandi M, Spreafico F. Suramin prevents neovascularisation and tumor growth through blocking of basic fibroblast growth factor activity. Br J Cancer 1992; 66: 367-72.
13. Bergh J. Suramin is a potent inhibitor of the cell proliferation in human non-small cell lung cancer cell lines. Proc (Abstract) Am Soc Clin Oncol 1989; 214.
14. Eisenberger MA, Fontana JA. Suramin, an active nonhormonal cytotoxic drug for treatment of prostate cancer: compelling reasons for testing in patients with hormone-refractory breast cancer. J Natl Cancer Inst 1992; 84: 3-5.
15. Lindman H, Taube A, Bergh J. Suramin inhibits the growth of human breast cancer cell lines. Anticancer Res 1994; 14: 363-6.
16. WHO Offset Publication No. 48. WHO handbook for reporting results of cancer treatment. Geneva: World Health Organization, 1979.
17. Klecker RW Jr, Collins JM. Quantification of Suramin by reverse-phase ion-pairing high-performance liquid chromatography. J Liquid Chromatography 1985; 8: 1685-1696.
18. Stein C, LaRocca R, Thomas R, McAtee N, Myers C. Suramin: an anticancer drug with a unique mechanism of action. J Clin Oncol 1989; 7: 499-508.
19. Myers C, Cooper M, Stein C, et al. Suramin: a novel growth factor antagonist with activity in hormone-refractory metastatic prostate cancer. J Clin Oncol 1992; 10: 881-9.
20. Eisenberger MA, Reyno LM. Suramin. Cancer Treat Rev 1994; 20: 259-73.
21. Rubio GJ, Pinedo HM, Virizuela J, van Ark-Otte J, Giaccone G. Effects of suramin on human lung cancer cell lines. Eur J Cancer 1995; 31A: 244-51.
22. Scher HI, Jodrell DI, Iversen JM, et al. Use of adoptive control with feedback to individualize Suramin dosing. Cancer Res 1992; 52: 64-70.
23. LaRocca R, Meer J, Gilliatt RW, et al. Suramin-induced polyneuropathy. Neurology 1990; 40: 954-960.